EUVIMEDEUVIMED entdecken
Fallbericht

Drug Eruption From Atorvastatin: With Initial Misdiagnosis of Tinea Cruris

Kimberly Hanson, Raymond G Mattes, Kimberly A B Cauthon

The Senior Care Pharmacist · 2023

DOI: 10.4140/tcp.n.2023.63 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Senior Care Pharmacist, 2023. Verfasst von Kimberly Hanson und 2 weiteren Autor:innen. Beteiligte Einrichtung: HEB Pharmacy, Pleasanton, Texas. Clinical Pharmacy Specialist, South Texas Veterans Health Care System, Pleasanton, Texas. Hauptthemen laut MEDLINE: Atorvastatin, Drug Eruptions, Exanthema, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To present the case of a Latin man 68 years of age who presented to the emergency department with a rash to the right side of his groin 10 weeks after switching from simvastatin 40 mg daily to atorvastatin 40 mg daily.

Background

Prior to switching to atorvastatin, the patient had been taking simvastatin for 21 years without rash. The rash progressed bilaterally to his arms and hands, legs, buttocks, back, and trunk before the patient was seen by dermatology and atorvastatin was discontinued.

Results

Within six weeks of discontinuation of atorvastatin, the rash resolved with remaining pigmentation changes. The adverse effect was documented in the patient’s chart, and dermatology recommended avoiding other statins in the future. Settings Ambulatory clinic pharmacy practice, emergency room, or urgent care centers. Practice Considerations Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor or statin that has been FDA approved for the prevention of atherosclerotic cardiovascular disease (ASCVD) and treatment of hypercholesterolemia since 1996. Despite widespread use of atorvastatin over many years, only a handful of published cases report drug eruption from its use. Previous case reports have found that retrial of statins may cause similar drug eruption.

Conclusion

Pharmacists should consider HMG-CoA reductase inhibitors as a possible cause of new onset rash and should not retrial an alternative statin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinDrug EruptionsExanthemaHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMalePyrrolesSimvastatinTinea CrurisAgedDrug Substitution

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsPyrrolesSimvastatin

Autor:innen und Institutionen

  • HEB Pharmacy, Pleasanton, Texas. Clinical Pharmacy Specialist, South Texas Veterans Health Care System, Pleasanton, Texas.

Zitieren

APA

Hanson, K., Mattes, R. G., & Cauthon, K. A. B. (2023). Drug Eruption From Atorvastatin: With Initial Misdiagnosis of Tinea Cruris. The Senior Care Pharmacist. https://doi.org/10.4140/tcp.n.2023.63

Vancouver

Hanson K, Mattes RG, Cauthon KAB. Drug Eruption From Atorvastatin: With Initial Misdiagnosis of Tinea Cruris. The Senior Care Pharmacist. 2023. doi:10.4140/tcp.n.2023.63

BibTeX
@article{Hanson2023,
  author = {Hanson, Kimberly and Mattes, Raymond G and Cauthon, Kimberly A B},
  title = {Drug Eruption From Atorvastatin: With Initial Misdiagnosis of Tinea Cruris},
  journal = {The Senior Care Pharmacist},
  year = {2023},
  doi = {10.4140/tcp.n.2023.63}
}
Kostenlos starten →